ONCOassist

ONCOassist A revolutionary app designed by oncology professionals for oncology professionals. The go-to app for all oncology professionals.

It gives them comfort where they can access relevant, up to date tools and content at their fingertips. It is the only mobile-first platform that saves time and improves the quality of patient care for frustrated and under pressure oncology HCPs. With the advent of genomic sequencing, combined with an aging population, and new therapies. The decision-making process for oncology HCP's is becoming i

ncreasingly complex. Unfortunately, they have no easy access to the tools and information they need to make an informed decision quickly. This means they use multiple different software and tools to aid their decisions, many of which are not safe and validated. This wastes time & reduces the quality of patient care. We focus on making ONCOassist easily accessible to all oncology HCP’s by being available across multiple devices(iOS, Android, and Desktop) and ensuring safety through CE and FDA compliance. Such is the need for ONCOassist our community of users are actively engaging with us to help define our future tools based on their burning needs. ONCOassist is improving the delivery of cancer care globally and helping us to reach our goal of leveling the standard of care worldwide.

🚨New in  !✅ The European Commission approves tablet formulation of BRUKINSA® (Zanubrutinib)  for all approved indication...
22/08/2025

🚨New in !

✅ The European Commission approves tablet formulation of BRUKINSA® (Zanubrutinib) for all approved indications.

💊 A step forward in treatment simplicity & convenience, enhancing patient care across Europe.

🔗 Read more: bit.ly/ONCOnews22AU-3

🚨New in  !📊 New insights from the BWEL trial: A weight loss intervention in women with stage II/III breast cancer shows ...
22/08/2025

🚨New in !

📊 New insights from the BWEL trial:

A weight loss intervention in women with stage II/III breast cancer shows impact on 1-year weight change.

➡️ Secondary analysis highlights the role of lifestyle in cancer outcomes.

🔗 Read more: bit.ly/ONCOnews22AU-2

🚨New in  !✅ Health Canada approves Columvi® (Glofitamab, Roche), First bispecific antibody in Canada 🧬 Indicated for rel...
22/08/2025

🚨New in !

✅ Health Canada approves Columvi® (Glofitamab, Roche), First bispecific antibody in Canada

🧬 Indicated for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after initial therapy

🔗 Read more: bit.ly/ONCOnews22AU-1

🚨New in  !✨ Health Canada approves OPDIVO® (Nivolumab) + YERVOY® (Ipilimumab) dual immunotherapy for CRC and HCC. 🧩 New ...
21/08/2025

🚨New in !

✨ Health Canada approves OPDIVO® (Nivolumab) + YERVOY® (Ipilimumab) dual immunotherapy for CRC and HCC.

🧩 New 1L option for unresectable/metastatic microsatellite instability-high (MSI-H)/ mismatch repair deficient (dMMR) colorectal cancer (CRC)

🩸 Approved for unresectable/advanced hepatocellular carcinoma (HCC)

🔗 Read more: bit.ly/ONCOnews21AU-1

🚨New in  !Final Analysis of Phase III KEYNOTE-585 results!📊 Pembrolizumab + chemotherapy improves outcomes vs chemo alon...
20/08/2025

🚨New in !

Final Analysis of Phase III KEYNOTE-585 results!

📊 Pembrolizumab + chemotherapy improves outcomes vs chemo alone as perioperative therapy in locally Advanced Gastric & Gastroesophageal Junction Cancer.

🔗 Read more: bit.ly/ONCOnews20AU-1

🚨 New in  !💡 Phase III IMvigor011 trial in muscle-invasive bladder cancer reports positive results.📊 Signatera™ ctDNA MR...
19/08/2025

🚨 New in !

💡 Phase III IMvigor011 trial in muscle-invasive bladder cancer reports positive results.

📊 Signatera™ ctDNA MRD–guided approach strongly predicts benefit from adjuvant Atezolizumab (Tecentriq®).

✅ Significant improvements in disease-free survival and overall survival for Signatera-positive patients.

🔗 Read more: bit.ly/ONCOnews19AU-3

🚨 New in  !🇪🇺 European Commission approves OGSIVEO® (Nirogacestat) for adults with desmoid tumors.✅ First & only therapy...
19/08/2025

🚨 New in !

🇪🇺 European Commission approves OGSIVEO® (Nirogacestat) for adults with desmoid tumors.

✅ First & only therapy authorized in the EU for this rare disease.

🔗 Read more: bit.ly/ONCOnews19AU-2

🚨 New in  !📊 APOLLO Trial evaluates Arsenic Trioxide + ATRA (All-Trans Retinoic Acid) for high-risk Acute Promyelocytic ...
19/08/2025

🚨 New in !

📊 APOLLO Trial evaluates Arsenic Trioxide + ATRA (All-Trans Retinoic Acid) for high-risk Acute Promyelocytic Leukemia (APL).

➡️ Combination shows strong potential in improving outcomes for this challenging subtype.

🔗 Read more: bit.ly/ONCOnews19AU-1

🎥 Oncology Tools | FONG Score tool Simplified with ONCOassistIn this quick overview, Dr. Lakshmi walks us through how ON...
19/08/2025

🎥 Oncology Tools | FONG Score tool Simplified with ONCOassist
In this quick overview, Dr. Lakshmi walks us through how ONCOassist simplifies complex oncology decisions using the Fong Clinical Risk Score — helping clinicians interpret key factors and guide treatment planning with ease.

Watch Now: https://youtu.be/9D_Ox6eQNbc

In this video, we walk you through:
✅ What the score is based on
✅ How to interpret it in seconds
✅ Why it helps guide key treatment decisions

💡 Designed for simplicity, accuracy, and speed—right from your ONCOassist app. Watch now to see how it fits into your clinical workflow.

Download the ONCOassist app:
📥 iOS: https://apple.co/4iuMxfS
📥 Android: https://bit.ly/oncoassistonandroid
📥Webapp: https://bit.ly/ONCOassistOnWeb

🌐 Learn more at: https://oncoassist.com/

🎥 Oncology ToolsLooking for a quick, evidence-based tool to estimate prognosis in colorectal liver metastases? In this short walkthrough, Dr. Lakshmi (Clini...

🚨 New in  !📊 Network meta-analysis reveals which first-line systemic therapy for advanced HCC best balances survival and...
18/08/2025

🚨 New in !

📊 Network meta-analysis reveals which first-line systemic therapy for advanced HCC best balances survival and quality of life.

➡️ Atezolizumab + bevacizumab stands out — key insights for patient-centered treatment decisions.

🔗 Read more: bit.ly/ONCOnews18AU-1

🚨 Breaking in Oncology! 💡 CONKO-007 Trial Results Are In: 📊 Chemoradiotherapy after induction therapy vs chemo alone → m...
14/08/2025

🚨 Breaking in Oncology!

💡 CONKO-007 Trial Results Are In:

📊 Chemoradiotherapy after induction therapy vs chemo alone → more patients go from unresectable ➡ resectable pancreatic cancer.

📈 Improved survival outcomes backed by randomized trial data.

🔗 Read more: bit.ly/ONCOnews14AU-1

🚨Today’s Oncology Update! 🧬 PADCEV™ (enfortumab vedotin) + KEYTRUDA™(pembrolizumab) first regimen to improve survival be...
13/08/2025

🚨Today’s Oncology Update!

🧬 PADCEV™ (enfortumab vedotin) + KEYTRUDA™(pembrolizumab) first regimen to improve survival before & after surgery in cisplatin-ineligible bladder cancer patients!

📈 Results to be discussed with global health authorities 🌍

🔗 Read more: bit.ly/ONCOnews13AU-1

Address

3rd Floor, 41/42, High Street
Killarney
V93T8K7

Alerts

Be the first to know and let us send you an email when ONCOassist posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to ONCOassist:

Share